vs
Side-by-side financial comparison of Celcuity Inc. (CELC) and Natera, Inc. (NTRA). Click either name above to swap in a different company.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendment...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $665.5M | ||
| Q3 25 | — | $592.2M | ||
| Q2 25 | — | $546.6M | ||
| Q1 25 | — | $501.8M | ||
| Q4 24 | — | $476.1M | ||
| Q3 24 | — | $439.8M | ||
| Q2 24 | — | $413.4M | ||
| Q1 24 | — | $367.7M |
| Q4 25 | — | $47.3M | ||
| Q3 25 | — | $-87.5M | ||
| Q2 25 | — | $-100.9M | ||
| Q1 25 | — | $-66.9M | ||
| Q4 24 | — | $-53.8M | ||
| Q3 24 | — | $-31.6M | ||
| Q2 24 | — | $-37.5M | ||
| Q1 24 | — | $-67.6M |
| Q4 25 | — | -3.4% | ||
| Q3 25 | — | -16.5% | ||
| Q2 25 | — | -20.2% | ||
| Q1 25 | — | -15.8% | ||
| Q4 24 | — | -13.6% | ||
| Q3 24 | — | -8.9% | ||
| Q2 24 | — | -10.6% | ||
| Q1 24 | — | -20.2% |
| Q4 25 | — | 7.1% | ||
| Q3 25 | — | -14.8% | ||
| Q2 25 | — | -18.5% | ||
| Q1 25 | — | -13.3% | ||
| Q4 24 | — | -11.3% | ||
| Q3 24 | — | -7.2% | ||
| Q2 24 | — | -9.1% | ||
| Q1 24 | — | -18.4% |
| Q4 25 | — | $0.36 | ||
| Q3 25 | — | $-0.64 | ||
| Q2 25 | — | $-0.74 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.41 | ||
| Q3 24 | — | $-0.26 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $-0.56 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
